The 5-HT 6 receptor has emerged as a promising target for cognitive disorders and combining a 5-HT 6 receptor antagonist with an acetylcholinesterase inhibitor (AChEI) represents a novel approach for the symptomatic treatment of Alzheimer's disease (AD). A recent phase 2 trial showed that the selective 5-HT 6 receptor antagonist idalopirdine (Lu AE58054) improved cognition in patients with moderate AD on stable treatment with the AChEI donepezil. Here we investigated the effects of idalopirdine in combination with donepezil on hippocampal function using in vivo electrophysiology and microdialysis. Network oscillations in the hippocampus were recorded during electrical stimulation of the brainstem nucleus pontis oralis (nPO) in the anesthetized rat and hippocampal acetylcholine (ACh) levels were measured in the freely-moving rat. In addition, potential pharmacokinetic interactions between idalopirdine and donepezil were assessed. Idalopirdine alone did not affect hippocampal network oscillations or ACh levels. Donepezil (0.3 and 1.0 mg/kg i.v.) dose-dependently increased hippocampal theta and gamma power during nPO stimulation. Idalopirdine (2 mg/kg i.v.), administered 1 h prior to donepezil, potentiated the theta and gamma response to 0.3 mg/kg donepezil and prolonged the gamma response to 1 mg/kg donepezil. Donepezil (1.3 mg/kg s.c.) increased extracellular ACh levels in the hippocampus and this was further augmented by administration of idalopirdine (10 mg/kg p.o.) 2 h prior to donepezil. These effects could not be attributed to a pharmacokinetic interaction between the compounds. This study demonstrates that idalopirdine potentiates the effects of donepezil on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Such potentiation could contribute to the procognitive effects of idalopirdine observed in donepezil-treated AD patients.
Introduction
Alzheimer's disease (AD) is the most common type of dementia and the number of patients is expected to rise significantly in the coming decades due to the ageing worldwide population. Amyloid plaques and neurofibrillary tangles, caused by aberrant accumulation of beta amyloid and tau proteins, respectively, result in extensive neurodegeneration and are associated with the dysfunction of several neurotransmitter systems. In particular the hippocampus is affected early during the course of the disease. In the absence of disease-modifying therapies, existing symptomatic treatments aim to alleviate these deficits in neurotransmission, which play a critical role in the debilitating cognitive impairment in AD. Specifically, acetylcholinesterase inhibitors (AChEIs) compensate for the deficit in cholinergic signaling and the NMDA receptor antagonist memantine modulates glutamatergic signaling, both with a positive outcome on cognitive function. However, due to the complexity and progressive nature of AD, current symptomatic agents have proven inadequate and need to be augmented with new therapies, especially at earlier stages of the disease.
Another neurotransmitter system for which there is evidence of dysfunction in AD is the serotonergic system (Arai et al., 1984; Cross et al., 1983; Ichimiya et al., 1986) and serotonin is strongly implicated in the regulation of learning and memory (Meneses, 2013; Leiser et al., 2015) . The superfamily of serotonin (5-HT) receptors consists of 7 subtypes. Of these, the 5-HT 6 receptor, which is positively coupled to the second messenger cyclic AMP through the G-protein GaS, is among the latest identified members (Monsma et al., 1993; Ruat et al., 1993) . This receptor has gained increasing attention as a putative target for the treatment of cognitive disorders due to its presence in brain regions that mediate learning and memory combined with its near exclusive localization within the central nervous system (Hirst et al., 2003; Helboe et al., 2015) . Positron emission tomography (PET), ligand binding and in-situ hybridization studies have demonstrated high densities of the 5-HT 6 receptor in the basal ganglia and moderate densities in the hippocampus and cerebral cortex, both in humans and rats Roberts et al., 2002; Hirst et al., 2003; Parker et al., 2012) . In a recent study, we demonstrated that 5-HT 6 receptor mRNA is predominantly expressed in GABAergic medium spiny neurons and in glutamatergic pyramidal cells, as well as in subpopulations of GABAergic interneurons (Helboe et al., 2015) . This distinct localization allows the 5-HT 6 receptor to regulate the balance between inhibitory GABAergic and excitatory glutamatergic signaling and thus affect multiple transmitter systems (reviewed in: Dawson, 2011) . Pharmacological manipulation in preclinical models has also provided compelling evidence for the role of the 5-HT 6 receptor in cognition and a number of 5-HT 6 receptor antagonists have reached clinical development for cognitive disorders, most notably AD (Mitchell and Neumaier, 2005; Fone, 2008; Arnt et al., 2010; Meneses et al., 2011; MaherEdwards et al., 2011; Ramirez, 2013; Wilkinson et al., 2014) . Of these, idalopirdine (Lu AE58054), a high affinity and selective antagonist of the 5-HT 6 receptor, is furthest advanced, and currently in phase III development for the treatment of mildmoderate AD.
Loss of cholinergic neurons is one of the pathological hallmarks of AD. Innervation from the nucleus basalis of Meynert and the medial septum to areas such as the cortex and hippocampus allows the cholinergic pathway to influence multiple aspects of cognitive function (Anand and Singh, 2013) . Indeed, depletion of acetylcholine (ACh) and decreased cholinergic activity, predominantly in the neocortex and hippocampus, are associated with cognitive decline in AD (Davies and Maloney, 1976; Whitehouse et al., 1982) . Addressing this loss through AChEI treatment has beneficial effects on cognitive function in AD patients (Tsuno, 2009) , although these effects are considered modest (Birks and Harvey, 2006; Raina et al., 2008; Tan et al., 2014) . Interestingly, a number of preclinical studies in rats have suggested that the neurochemical and procognitive effects of an AChEI can be potentiated by 5-HT 6 receptor antagonism (Marcos et al., 2008; de Bruin et al., 2011; Dawson, 2011) . This concept is currently being pursued in clinical studies, which suggest that combining a 5-HT 6 receptor antagonist with an AChEI provides a promising new approach for the symptomatic treatment of AD (Maher-Edwards et al., 2011; Wilkinson et al., 2014) . Indeed, in a recent phase II trial, idalopirdine improved the cognitive performance of patients with moderate AD that were on stable treatment with the AChEI donepezil (Wilkinson et al., 2014) .
Neuronal oscillations, as measured in the electroencephalogram (EEG), represent synchronized activity of neuronal networks and are essential for information processing (Draguhn et al., 2014) . Of these, theta (4e8 Hz) and gamma (30e48 Hz) oscillatory rhythms are of particular interest as they have each been associated with cognitive function (Bland, 1986; Colgin et al., 2009; Jutras et al., 2009; Nyhus and Curran, 2010) . In mild-moderate AD, oscillatory changes most consistently described include a reduction of cortical EEG power in the alpha and gamma bands and clinical studies have shown a partial normalization of the oscillatory activity as a consequence of AChEI treatment (reviewed by: Babiloni et al., 2013; Basar et al., 2013) . In the laboratory setting, theta and gamma oscillations in the hippocampus can be induced by high frequency electrical stimulation of the brainstem nucleus pontis oralis (nPO) in the anesthetized rodent (Vertes, 1982; Kinney et al., 1999) . This activates an ascending pathway from the brainstem to the septum/ diagonal band of Broca, providing the hippocampus with cholinergic, glutamatergic and GABAergic input (Vertes, 1981; Bland and Oddie, 1998; Stoiljkovic et al., 2015) . In addition, serotonergic modulation of the hippocampal theta rhythm during brainstem stimulation has been demonstrated with several serotonin receptor ligands (Sorman et al., 2011; Johnson et al., 2012; Zhu and McNaughton, 1994) . These studies are performed under anesthesia which prevents the confounding effects of movement on oscillatory activity and inhibits spontaneous theta oscillations (Buzsaki, 2002) . Donepezil and several pharmacological agents that enhance cognition, were shown to increase the power and peak frequency of hippocampal theta oscillations during stimulation of the nPO (McNaughton et al., 2007; Kinney et al., 1999) suggesting that this assay is suitable to investigate the effects of procognitive compounds on hippocampal network activity relevant for cognition.
The present study further investigates the underlying mechanisms by which 5-HT 6 receptor antagonism may improve cognition and provide added benefit when combined with AChEIs. For this purpose, we examined the effects of idalopirdine alone and in combination with donepezil on hippocampal oscillations during stimulation of the nPO in the anesthetized rat and on extracellular levels of ACh in the hippocampus of the awake and freely moving rat. In addition, we examined the potential pharmacokinetic interactions between idalopirdine and donepezil.
Methods

Animals
Animal studies were carried out in accordance with the European Communities Council Directive (86/609/EEC) for the care and use of laboratory animals and the Danish legislation regulating animal experiments. Male Sprague Dawley rats (Charles River, Germany) were housed in pairs under controlled temperature (22 ± 1.5 C) and humidity conditions (55e65%) and kept on a 12:12 h light/dark cycle (lights on at 06:00). Food and water was available ad libitum.
Drugs
For electrophysiological studies, donepezil (Medicinal chemistry, H. Lundbeck A/S) was dissolved in 0.9% saline and administered intravenously (i.v.) at doses of 0.3 and 1 mg/kg in a volume of 1 ml/ kg. Idalopirdine was dissolved in isotonic 5% glucose and administered i.v. at doses of 1 and 2 mg/kg in a volume of 1 ml/kg. 5% glucose was used as vehicle.
For microdialysis studies, idalopirdine was dissolved in 5% 2-hydroxypropylbeta-cyclodextrin (Hp-beta-CD) and administered orally (p.o.) at doses of 1, 5 or 10 mg/kg in a volume of 5 ml/kg. Donepezil was dissolved in 5% Hp-beta-CD and administered subcutaneously (s.c.) at a dose of 1.3 mg/kg in a volume of 2.5 ml/kg 5% Hp-beta-CD was used as vehicle. All doses are expressed as mg free base/kg body weight.
Electrophysiology
Surgery
Experiments were performed in rats weighing 250e450 g, anesthetized with an intraperitoneal injection of 1.5 g/kg urethane (supplemented if needed to reduce spontaneously occurring theta oscillations). Each animal was surgically implanted with a femoral catheter (P50 tubing) for i.v. administration of compounds. Animals were placed in a stereotaxic frame (Kopf, Tugunga, CA, USA) and the body temperature was monitored by rectal probe and maintained at 37 C via a homeothermic blanket. The skull directly over the bregma-lambda suture was exposed followed by burring a small hole in the right frontal bone for placement of a silver grounding electrode. Additional holes were burred into the left parietal bone for placement of the recording electrode in the hippocampal fissure (coordinates relative to bregma in mm (Paxinos and Watson 1986 : AP (anterior posterior) À3.5 mm, L (lateral) 2.0e2.2 mm, V (ventral) 2.9e3.1 mm) and the stimulating electrode in the nPO (AP 8.0 mm; L 1.6 mm; V 6 mm). Following surgery, the animals were kept in the stereotaxic frame for the duration of the experiment and allowed to stabilize for 1e2 h prior to beginning each recording.
Recording and stimulation
Field potentials (EEG activity) were recorded using unipolar stainless steel electrodes (0.005/0.125 mm, Plastics One, Roanoke, VA) and a Grass model P55 AC amplifier (Grass Instruments, West Warrick, RI) with the filters set at 0.1 and 100 Hz (high pass/low pass respectively) and the 50 Hz notch filter in the off position. The signals were digitized at a rate of 1 kHz (CED Micro 1401, Cambridge Electronic Design, Ltd, Cambridge, UK) and stored on a PC for subsequent off-line analysis using Spike2 software (version 7.10, Cambridge Electronic Design). The nPO was stimulated via a bipolar concentric 400 mm tungsten electrode (TM53CCINS, World Precision Instruments, Inc., USA). Hippocampal oscillations were induced every 100 s by application of a 6 s train of 0.3 ms square pulses at 250 Hz controlled via the Spike2 software and a A365 stimulus isolator (World Precision Instruments, Inc., USA). The depth of the recording electrode was adjusted in order to yield high amplitude theta power, which was typically obtained at the level of the hippocampal fissure as described previously (Kowalczyk and Konopacki, 2002) . The stimulation intensity was adjusted so that the peak frequency of the evoked signal was between 5 and 6 Hz, and typically ranged from 100 to 150 mA in amplitude. After a stable baseline was established (>1 h), vehicle or idalopirdine was administered and EEG was recorded for a further 1 h before a second dose of vehicle or donepezil was injected. Only studies where a stable baseline was established before drug injection were used in the data analysis. At the end of each experiment a 200 mA current was applied through the electrodes, rats were euthanized with a bolus injection of urethane and brains were removed for verification of electrode placement. Only experiments in which electrodes were correctly placed were included in the data analysis.
Data analysis
The signal processing of local field potential (LFP) activity was computed in MATLAB, using functions implemented in the Fieldtrip toolbox (http://www.ru.nl/fcdonders/fieldtrip/) and the sigTOOL toolbox (http://sigtool.sourceforge.net/sigtool.html).
2.3.3.1. Pre-processing. Epochs with high amplitude electrical noise were visually identified and manually removed before data analysis in Spike2. The recordings were imported in MATLAB and segmented into epochs extending from 5 s before nPO stimulation to 5 s after nPO stimulation. The epochs were baseline corrected, to remove any standing offset, by subtracting the average amplitude in the pre-nPO period from the entire epoch. Artefact correction was then performed for each recording, based on the standard score (z EEG,t ) of each sample:
Any sample with an extreme value, i.e. 18 standard scores from the mean, was considered an artefact. The artefacts were excluded from analysis.
Spectral analysis and statistics.
To investigate the effect of nPO stimulation itself and the impact of the treatments, power spectra were computed using a fast Fourier transform between 1 and 50 Hz with a Hamming window on 5 s epochs downsampled to 500 Hz. Where relevant, frequency bands were compared by paired t-test or Wilcoxon signed rank test. Further investigation of a treatment effect was completed by performing a short-time Fourier transform using a fixed 1 s Gaussian window on each epoch in the frequency interval 1e48 Hz. The treatment response over time was computed using the average raw power over time before and during each stimulation (epoch); pre-nPO (À5e0 s) and during nPO (the last 5 s of the 6 s nPO-period were used). To visualize a power change from baseline, the power was normalized to the average baseline power in each frequency bin. Subsequently, oscillatory activity was divided into the 5 main frequency bands: delta; 04 Hz, theta; 48 Hz, alpha; 813 Hz, beta 1330 Hz: gamma; 3048 Hz and compared between treatments. The data are expressed as group mean ± SEM. Data were analyzed by two-way repeated measures ANOVA with treatment as between-subject factor and time (35 stimulation epochs) as within-subject factor, followed by a Holm Sidak post hoc analysis, using SigmaPlot (version 11.0).
Microdialysis
Surgery
Rats weighing 275e300 g were anesthetized with hypnorm/ dormicum (2 ml/kg) and intracerebral guide cannulas (CMA/12) were stereotaxically implanted into the brain, aiming to position the dialysis probe tip in the dorsal hippocampus (coordinates: AP -4.3 mm, L -2.6 mm, V -4.0 mm) according to Paxinos and Watson (Paxinos and Watson, 1986) . Anchor screws and acrylic cement were used for fixation of the guide cannulas. The body temperature of the animals was monitored by rectal probe and maintained at 37 C via a homeothermic blanket. The rats were allowed to recover from surgery for 2 days, single-housed.
Microdialysis experiments
On the day of the experiment a microdialysis probe (CMA/12, 0.5 mm diameter, 2 mm length) was inserted through the guide cannula. The probes were connected via a dual channel swivel to a microinjection pump. Perfusion of the microdialysis probe with filtered Ringer solution (145 mm NaCl, 3 mM KCl, 1 mM MgCl2, 1.2 mM CaCl2) was begun shortly before insertion of the probe into the brain and continued for the duration of the experiment at a constant flow rate of 1 ml/min. After 180 min of stabilization, the experiments were initiated. Dialysates were collected every 20 min. After the experiments the animals were euthanized and the brains were removed for verification of probe placement. Only those animals with correct placement were included in the data analysis.
Analysis of ACh in rat brain microdialysate
ACh concentrations in microdialysis samples were determined by means of ultra-performance liquid chromatography (UPLC) coupled to tandem mass spectrometry (MS/MS) without any sample preparation. A standard curve was prepared in Ringer's solutions containing ACh concentrations in the range of 0.01e10 ng/ml. 2 ml of sample or standard, refrigerated to 10 C in the autosampler, was injected onto the chromatographic system (Waters Aquity UPLC, Milford, MA) equipped with a Primesep 200 column (2,1 Â 50 mm, 3 mM particles, 100 A pore size; SIELC Technologies, Wheeling, IL) operated at room temperature at a flow rate of 0.6 ml/ min. The mobile phase consisted of 0.1% formic acid in water and acetonitrile pumped through the column as a gradient resulting in a retention time of 0.95 min. ACh was detected in positive-ion electrospray ionization MS mode with parent/daughter transition of 146.2/87.1 using a Waters TQ-S system (Milford, MA). The total runtime was 5 min for each sample. The limit of quantitation was 0.01 ng/ml (signal-to-noise ratio >6). Data acquisition and analysis was performed using Masslynx software, version 4.1 (Waters, Milford, MA).
Data analysis and statistics
In the data analysis the mean value of 3 consecutive ACh samples immediately preceding donepezil/vehicle administration served as the basal level for each experiment and data were converted to percentage of basal (mean basal pre-injection values normalized to 100%). The data are expressed as group mean ± SEM. Data were analyzed by two-way repeated measures ANOVA followed by a Student-Newman Keuls post hoc analysis using SigmaPlot (version 11.0).
2.5. Plasma and brain exposure of idalopirdine and donepezil 2.5.1. Exposure studies Plasma and brain concentrations of donepezil and idalopirdine were investigated in separate groups of rats. In parallel to the electrophysiology studies, rats were dosed with idalopirdine (1 or 2 mg/kg i.v.) or vehicle 1 h prior to donepezil (0.3 or 1 mg/kg i.v.) or vehicle. Blood samples were collected in EDTA coated tubes at t ¼ 0, 5, 15, 30 and 60 min and brain tissue at t ¼ 60 min after donepezil administration, corresponding to t ¼ 60, 65, 75, 90 and 120 min after idalopirdine administration. In parallel to the microdialysis study, idalopirdine (10 mg/kg p.o.) or vehicle were administered 2 h prior to donepezil (1.3 mg/kg s.c.) or vehicle. Blood samples were collected at t ¼ 30 and 60 min and brain tissue at t ¼ 60 min after donepezil administration, corresponding to t ¼ 150 and 180 min after idalopirdine administration. Blood samples were centrifuged for 10 min at 5000 g at 4 C, and plasma was stored together with the brain samples at À80 C until sample preparation and bioanalysis.
Quantitative bioanalysis
Rat plasma and brain concentrations of idalopirdine and donepezil were determined using UPLC-MS/MS. Brain homogenate samples were prepared by homogenizing the whole brain with 70% acetonitrile (1:4, v/v) followed by centrifugation and collection of the supernatant. Plasma or brain samples (25 ml) were precipitated with 150 ml acetonitrile containing internal standard. For idalopirdine, a 13C-labelled internal standard was used. After centrifugation, 100 ml supernatant from each sample was transferred to a new plate and mixed with 100 ml 0.1% formic acid. After a quick centrifugation the samples were placed in the autosampler. Chromatography was performed on a Waters Aqurity C18 SB HSS column (30 Â 2.1 mm, 1.8 mm particles) using a mobile phase gradient of 0.1% formic acid in water and acetonitrile pumped through the column with a flow rate of 0.6 ml/min. The retention time was 1.13 and 0.93 min for idalopirdine and donepezil, respectively. MS/MS detection was done with an Applied Biosystems Sciex API 4000 instrument in positive-ion electrospray ionization mode (AB Sciex, Foster City, CA). Mass to charge ratios (m/z) of 399.1 > 221.1 and 380.2 > 91.2 were used for detection of idalopirdine and donepezil, respectively. Nitrogen was used for the nebulizer and collision gases. The peak area correlated linearly with the concentration in the range of 0.5e1000 ng/ml in plasma and 2.5e5000 ng/g in brain for both analytes. Data acquisition and analysis was performed using Analyst software, version 6.1 (AB Sciex, Foster City, CA).
Data analysis and statistics
Plasma concentrations of idalopirdine and donepezil in ng/ml are depicted over time. The mean areas under the curve (AUC) were calculated and compared by one-way ANOVA or student's t-test, as appropriate. At the terminal time point brain concentrations of idalopirdine and donepezil in ng/g were compared by one-way ANOVA or student's t-test, followed by a Bonferroni post-hoc analysis.
Results
3.1. Local field potential oscillations in the dorsal hippocampus of the anesthetized rat 3.1.1. Effect of electrical stimulation of nPO on local field potential oscillations in the hippocampus During baseline recording, delta oscillations (<4 Hz) were prominent whilst theta oscillations were limited in the CA1 area of the hippocampus, with no clear peak in the 4e8 Hz theta band. As previously reported (Vertes, 2005; Kinney et al., 1999; Siok et al., 2009 Siok et al., , 2012 , electrical stimulation of the nPO resulted in highly regular and robust hippocampal CA1 theta oscillations in the EEG (Fig. 1A1 and B) . nPO stimulation resulted in a peak theta frequency of 5.0 ± 0.07 Hz (n ¼ 44) and an overall 4.5 fold increase in theta power (Wilcoxon singed rank test, p < 0.001). In contrast, gamma oscillations (30e48 Hz) were not significantly increased by nPO stimulation per se (paired student's t-test: P ¼ 0.614, Fig. 1A ). The theta power during nPO stimulation could be further augmented by administration of donepezil alone or in combination with idalopirdine, whereas gamma power was only enhanced during nPO stimulation by treatment with the combination of idalopirdine and donepezil, as exemplified by Fig. 1B . There were no treatment effects on gamma power above 50 Hz (data now shown). Since injection of vehicle did not significantly alter responses to nPO stimulation (theta: paired student's t-test: P ¼ 0.251, Fig. 1 A2) , compound effects were normalized to the 30 min baseline directly before compound administration in the following analyses.
Effect of idalopirdine and donepezil on theta and gamma during nPO stimulation
There were no treatment effects on spontaneous oscillations (Fig. 2, left panel) , therefore compound effects are described during nPO stimulation (Fig. 2, right panel and Fig. 3 ). Idalopirdine (1 or 2 mg/kg i.v.) alone did not have a significant effect on theta or gamma oscillations during nPO stimulation in the 60 min period prior to donepezil administration (Figs. 2 and 3) . We have previously observed that, in this time window, idalopirdine concentrations in the brain correspond to high receptor occupancy (data not shown). Donepezil (0.3 or 1.0 mg/kg i.v.) alone dose-dependently increased theta and gamma power when compared to vehicle treatment (theta: F[treatment] 2,553 ¼ 3.569, P ¼ 0.049 and gamma: F[treatment] 2,553 ¼ 5.386, P ¼ 0.015, Figs. 2 and 3) , without shifting peak-frequencies (data not shown). Donepezil 1 mg/kg increased theta power compared to 0.3 mg/kg donepezil (P < 0.05) at the peak effect, 6e7 min after administration, and compared to vehicle treatment (P < 0.05) extending to 12 min after administration. Similarly, donepezil 1 mg/kg increased gamma power compared to 0.3 mg/kg donepezil (P < 0.05) from 610 min after administration and compared to vehicle treatment (P < 0.05) up to 25 min after administration. There was no significant effect of donepezil 0.3 mg/ kg on either theta (P ¼ 0.691) or gamma power (P ¼ 0.059), although there was a trend towards an increase in gamma power (150%). Fig. 1A, top panel) . This effect persisted until 15 min after injection. Plasma concentrations of donepezil were similar in the presence and absence of idalopirdine in this time window, indicating that this was not caused by a PK interaction (Fig. 5A) . In contrast, the lower dose of 1.0 mg/kg idalopirdine did not modify the response to donepezil 0.3 mg/kg on theta power (Fig. 3A, top  panel and supplementary Fig. 1A, top panel) . Fig. 3B, top panel) , although the combination of idalopirdine 2.0 mg/kg and donepezil 1.0 mg/kg did elevate theta power as compared to vehicle treatment during the peak response (5e15 min after donepezil administration, Fig. 3B , top panel and supplementary Fig. 1B, top panel) .
Effect of idalopirdine in combination with donepezil on hippocampal gamma during nPO stimulation
Idalopirdine 2.0 mg/kg in combination with donepezil 0.3 mg/ kg significantly increased gamma power during nPO stimulation as compared to vehicle treatment (P < 0.05), while there was no sig- Fig. 1A, bottom panel) . This effect persisted for the duration of the experiment. Plasma concentrations of donepezil were similar in the presence and absence of idalopirdine in this time window, indicating that this was not caused by a PK interaction (Fig. 5A) . In contrast, the lower dose of 1.0 mg/kg idalopirdine did not modify the response to donepezil 0.3 mg/kg on gamma power (Fig. 3A, bottom panel and supplementary Fig. 1A, bottom  panel) .
The combination treatment of idalopirdine 2 mg/kg and the higher dose of 1.0 mg/kg donepezil increased gamma power during nPO stimulation as compared to vehicle treatment (P < 0.01) and donepezil 1.0 mg/kg alone (P < 0.05) (F[treatment] Fig. 1B, bottom panel) . Idalopirdine 2 mg/kg prolonged the effects of donepezil 1 mg/kg on gamma power for the duration of the treatment period without changing the peak- Fig. 2 . Effect of idalopirdine, donepezil and the combination before and during nPO stimulation on the spectral power of hippocampal oscillations. Effects of the treatments on hippocampal oscillations (Hz) as a function of time; prior to nPO stimulation (left column) and during nPO stimulation (right column). nPO stimulations were repeated every 100 s and each vertical time bin in a heatplot represents the average spectral power of one such epoch, either pre-nPO (À5e0 s) or during nPO (1e6 s). Idalopirdine (IDL) or vehicle (veh) were administered at time 0, donepezil (DPZ) or veh at time 60. Heatplots show the average spectral power of each treatment group (n ¼ 7e9) standardized to the baseline period before drug or vehicle administration (À30e0 min relative to 1st injection).
effect. There was a transient increase in exposure of donepezil 1.0 mg/kg in combination with idalopirdine 2 mg/kg during the first 5 min after donepezil administration (Fig. 5B) , however this is unlikely to explain the lasting effect of the combination treatment on gamma power.
Extracellular levels of ACh
Rats were pretreated with idalopirdine (p.o.) 2 h before administration of donepezil/vehicle (s.c.). The absolute basal levels of extracellular levels of ACh in the dorsal hippocampus without considering probe recovery were 0.05 ± 0.005 (n ¼ 28) and 0.05 ± 0.004 (n ¼ 26) ng/mL dialysate in animals pretreated with vehicle and idalopirdine (10 mg/kg), respectively. Thus, idalopirdine administered alone did not affect hippocampal ACh levels. Administration of donepezil and donepezil in combination with idalopirdine increased the extracellular levels of hippocampal ACh (F[treatment] 2,84 ¼ 15.712, P < 0.001, Fig. 4A ). Injection of donepezil at 1.3 mg/kg increased hippocampal ACh levels by approximately 900% (P ¼ 0.089, Fig. 4A ). Administration of idalopirdine (10 mg/kg p.o.) 2 h prior to injection of donepezil significantly enhanced the donepezil-induced increases in ACh levels (P ¼ 0.006, Fig. 4A ). In a separate study administration of idalopirdine at 10 mg/kg p.o., but not 1 or 5 mg/kg, potentiated the donepezil-induced increase in levels of ACh (F[treatment] 4,213 ¼ 20.599, P < 0.001, Fig. 4B ). Donepezil alone significantly (P < 0.001) increased the levels of ACh and pretreatment with idalopirdine at 10 mg/kg significantly augmented this increase in ACh levels (P < 0.001). Similarly, we have observed a potentiation when idalopirdine (10 mg/kg p.o.) was combined with a lower dose of donepezil (0.5 mg/kg, s.c.) (data not shown, F[treatment] 2,79 ¼ 5.675, P ¼ 0.015). In a parallel study, there was shown a pharmacokinetic (PK) interaction between the compounds when idalopirdine was administered 2 h prior to injection of donepezil (1.3 mg/kg s.c.). An approximate 30% increase in donepezil plasma and brain exposure was observed in animals pretreated with idalopirdine ( Fig. 7A and C) . We therefore investigated the potential impact of the 30% increase in donepezil exposure on extracellular levels of ACh in a separate study. An attempt to mimic an increase of approximately 30% was made by injecting donepezil at 1.3 and 1.7 mg/kg (s.c.). Despite an increase in brain exposure of donepezil of approximately 60% after administration of 1.7 mg/kg, the detected increase in hippocampal ACh levels was not significant compared with the levels induced by 1.3 mg/kg donepezil ( Supplementary Fig. 2 ).
Exposure of idalopirdine and donepezil following i.v. administration
Plasma and brain concentrations of idalopirdine and donepezil were determined in a separate group of rats parallel to the electrophysiology studies (Figs. 6 and 7) . Donepezil plasma concentrations increased dose-dependently and pretreatment with idalopirdine (1 or 2 mg/kg, i.v.) did not modulate plasma AUC of donepezil dosed at 0.3 mg/kg, i.v. (Fig. 5A, F [AUC] 2,11 ¼ 2.927, P ¼ 0.1049) or at 1 mg/kg, i.v. (Fig. 5B, t [AUC] ¼ 0.6881, P ¼ 0.5171), although in the latter paradigm, a transient increase in donepezil concentration was observed during only the first 5 min after donepezil administration in rats pretreated with idalopirdine (t ¼ 3.103, P < 0.05). This did not translate to an increase in brain exposure as brain concentrations of donepezil increased dose- dependently and were not affected by idalopirdine pretreatment (Fig. 6A, F 4 ,19 ¼ 43.98, P < 0.0001. P < 0.05 donepezil 1.0 vs. donepezil 0.3, irrespective of pretreatment, Bonferroni post hoc). Plasma concentrations of idalopirdine increased dose-dependently and the plasma AUC of idalopirdine 2 mg/kg was not modulated by administration of donepezil 0.3 or 1 mg/kg (Fig. 5D, F [AUC] 2,11 ¼ 1.193, P ¼ 0.3472). When idalopirdine 1 mg/kg was followed by donepezil 0.3 mg/kg, a marginal elevation in idalopirdine plasma concentrations was observed (Fig. 5C, t [AUC] ¼ 2.807, P < 0.05). However, this did not translate to an increase in brain exposure as brain concentrations of idalopirdine increased dose-dependently without being affected by donepezil treatment (Fig. 6B, F 4 ,19 ¼ 13.32, P < 0.0001. P < 0.05 idalopirdine 2 vs. 1 mg/kg, irrespective of donepezil treatment, Bonferroni post hoc).
Exposure of idalopirdine and donepezil following p.o. and s.c. administration, respectively
Plasma and brain concentrations of idalopirdine 10 mg/kg p.o. and donepezil 1.3 mg/kg s.c. were determined in a separate group of rats parallel to the microdialysis study. Pretreatment with idalopirdine increased plasma and brain concentrations of donepezil by approximately 30% (plasma: Fig. 7A, t [AUC] ¼ 2.341, P < 0.05, brain: Fig. 7C , t ¼ À2.897, P < 0.05). In contrast, plasma and brain concentrations of idalopirdine were not modulated by donepezil 
Discussion
In the present study we demonstrate that the 5-HT 6 receptor antagonist idalopirdine potentiates the effects of donepezil on neuronal oscillations and extracellular levels of ACh in the hippocampus of the rat, two pharmacodynamic biomarkers that are associated with cognitive function.
In the current studies, donepezil had no impact on spontaneously occurring oscillatory activity in the urethane-anesthetized rat but did significantly increase theta and gamma power during nPO stimulation without significantly shifting the peak frequencies. Similarly, it has previously been shown that donepezil enhances hippocampal theta and gamma power during nPO stimulation in the anesthetized rat (Kinney et al., 1999; McNaughton et al., 2007) and both spontaneous theta and gamma power in the awake freely moving rat (Ahnaou et al., 2014) . The effect of i.v. donepezil on theta and gamma oscillatory activity was dose-dependent up to 1 mg/kg. In pilot experiments, we did not observe further increases with 2 or 3 mg/kg doses of donepezil during nPO stimulation (unpublished data), which led us to conclude that there was an upper limit to the effects of donepezil on hippocampal theta and gamma power. This is in agreement with two other studies demonstrating a ceiling to the effects of donepezil on hippocampal oscillations in the nPO stimulation assay and in a slice preparation (Kinney et al., 1999; Spencer et al., 2010) . It should be noted that, in the Kinney study, the effective dose-range of donepezil in the nPO assay was considerably higher than in the current study (0.1e10 mg/kg, with an apparent ceiling at 3 mg/kg) and that the duration of the donepezil effect was longer, both of which are likely explained by the different routes of donepezil administration between the studies (i.p. vs. i.v.).
Here we show that the effects of donepezil can be further potentiated by 5-HT 6 receptor antagonism. Idalopirdine (2 mg/kg i.v.), while not having an effect alone, markedly increased theta and gamma power in combination with the threshold dose of 0.3 mg/kg donepezil. At this dose of donepezil, plasma concentrations were within the range of clinically relevant concentrations (25e50 ng/ ml) Tiseo et al., 1998) which were not changed by co-dosing of idalopirdine. Furthermore, idalopirdine (2 mg/kg) significantly prolonged the effect of donepezil 1 mg/kg on gamma power in the time frame where donepezil exposure was not affected by idalopirdine pretreatment. Therefore, we conclude that idalopirdine potentiates and/or prolongs the effects of donepezil on neuronal oscillations in the hippocampus, at a dose of donepezil that correlates to clinically relevant plasma concentrations, which cannot be attributed to a pharmacokinetic interaction between the compounds. This effect was only observed with the higher dose of idalopirdine (2 mg/kg) where plasma concentrations reached approximately 90 ng/ml, which is above previously reported plasma concentration of 20 ng/ml leading to 50% occupancy of the 5-HT 6 receptor in vivo in rats (Arnt et al., 2010) . In continuation of this, it will be of great interest to study how idalopirdine alone, and in combination with donepezil, affects oscillatory activity in the awake rat during performance of a cognitive task. Few studies have addressed the effects of 5-HT 6 ligands on EEG in awake animals. Ly et al. found no effect of the 5-HT 6 receptor antagonist SAM-531 in either awake or anesthetized rats, in line with the present findings, whereas the 5-HT 6 agonist EMD386088 was shown to decrease theta peak frequency and suppress sleep (Ly et al., 2013) .
In the freely moving rat, we demonstrated that idalopirdine enhanced donepezil-induced increases in extracellular levels of hippocampal ACh. This effect was dose-dependent since only the highest dose (10 mg/kg p.o.) of idalopirdine tested induced a significant increase in ACh, indicating that a high 5-HT 6 receptor occupancy (>70%) is required (Arnt et al., 2010) . A small PK interaction was observed with the dosing regimen used for the microdialysis study, as donepezil brain exposure increased by approximately 30% in the presence of idalopirdine. When mimicking this increase in brain exposure of donepezil by injecting a higher corresponding dose of donepezil, the observed increase in ACh levels was not significant. Thus, it was concluded that the significant increase in ACh levels induced by idalopirdine cannot be explained solely by a pharmacokinetic interaction between the compounds. Consistent with the data from the present study, a similar observation was reported by Dawson showing that the 5-HT 6 receptor antagonist SB-742457 alone exerted a minimal effect on cortical ACh levels, but enhanced the effect of donepezil on ACh levels (Dawson, 2011) . Positive effects of 5-HT 6 receptor antagonism have also been observed in two other microdialysis studies, which demonstrated that systemic treatment with 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine (Riemer et al., 2003) and SB-399885 increased ACh levels in the rat brain. However, in these two studies an AChEI was included in the microdialysis perfusion solution to increase the extracellular ACh levels to detectable levels. Thus, these studies may rather have demonstrated that a 5-HT 6 receptor antagonist potentiates the effect of an AChEI on ACh levels.
The effects of 5-HT 6 receptor antagonists on extracellular ACh are most likely indirect, as there is no evidence for the presence of 5-HT 6 receptors on cholinergic neurons (Marcos et al., 2006; Helboe et al., 2015) . Therefore, the effect of 5-HT 6 receptor antagonism will depend not only on serotonergic tone, but also on the dynamics of other systems, particularly GABA and glutamate, in line with the localization of the 5-HT 6 receptor (Helboe et al., 2015) . Indeed, it has been demonstrated that a 5-HT 6 receptor agonist enhances extracellular GABA levels both after acute and subchronic treatment (Schechter et al., 2008) . We have also demonstrated that acute administration of the 5-HT 6 receptor agonist WAY-181187 increases extracellular GABA levels in the cortex, an effect which was blocked by idalopirdine (Herrik et al., 2013) . Conversely, WAY-181187 was found to reduce stimulated glutamate release in a hippocampal slice preparation (Schechter et al., 2008) whereas two 5-HT 6 receptor antagonists have been reported to increase extracellular levels of glutamate (Dawson et al., 2001; Chuang et al., 2006) . Thus, local enhancement of cholinergic function by 5-HT 6 receptor antagonism may depend on inhibition of GABAergic and/ or facilitation of glutamatergic signaling in relevant brain areas.
The observation that 5-HT 6 receptor antagonists primarily enhance the effect of donepezil on ACh levels and hippocampal oscillatory activity, rather than being efficacious on their own, may suggest that the effect of 5-HT 6 receptor antagonism requires a certain cholinergic tone provided by the AChEI (current study; Dawson, 2011) . However, idalopirdine monotherapy fully reversed a cognitive deficit induced by subchronic phencyclidine treatment in the rat novel object recognition test (Arnt et al., 2010) . Moreover, we have recently observed that, in the prefrontal cortex of the rat, idalopirdine (2 mg/kg i.v.) increases nPO stimulation-induced gamma oscillations as monotherapy as well as adjunctive therapy to donepezil (Foraster et al., 2014) . This leads us to speculate that the effect of 5-HT 6 antagonists depends on the context (e.g. brain region, behavioral task or disease state), which may differ in serotonergic tone, as well as to the degree in which other neurotransmitter systems are engaged. In addition, it will be of interest to study whether idalopirdine can also act through inverse agonism and achieve some of its neuropharmacological effects independent of the endogenous serotonergic tone, which has been suggested for a number of 5-HT 6 receptor antagonists in cellular systems (Romero et al., 2007; Duhr et al., 2014) .
Idalopirdine is likely to modulate hippocampal oscillatory activity through its effect on cholinergic signaling, as ACh is critical for theta and gamma oscillations. Indeed, a selective toxin lesion of septal cholinergic neurons reduced hippocampal theta power (Lee et al., 1994) whereas in vivo optogenetic activation of these neurons enhanced theta oscillations in the hippocampus (Vandecasteele et al., 2014) . Cholinergic signaling is also critical for hippocampal gamma oscillations as these can be induced in hippocampal slice preparations by cholinergic receptor activation with carbachol or with the AChEIs physostigmine and donepezil (Fellous and Sejnowski, 2000; Traub et al., 2000; Spencer et al., 2010; Pietersen et al., 2014) . We therefore postulate that, by enhancing the effects of donepezil on extracellular ACh levels, idalopirdine further potentiates the effects of this AChEI on hippocampal oscillatory activity. Interestingly however, brain concentrations of idalopirdine required to achieve an effect in nPO model were 2 fold lower than in the microdialysis paradigm. Although high receptor occupancy is assumed under both conditions, one possible explanation might be that the electrical stimulation used in the nPO model mimics an active cholinergic state which is sensitive to 5-HT 6 receptor blockade at lower concentrations of the antagonist when compared to microdialysis in freely moving rats. In addition, the observation that higher brain concentrations of idalopirdine are required to elevate ACh levels in the freely moving rat, suggests that amplification of cholinergic signaling is not the only mechanism through which idalopirdine potentiates the effects of donepezil on hippocampal neuronal oscillations. Indeed, idalopirdine is likely to modulate neuronal oscillations through direct effects on pyramidal cells and GABAergic interneurons that express the 5-HT 6 receptor (Helboe et al., 2015) . Neuronal oscillations reflect the summed synaptic potentials from networks of pyramidal cells and interneurons (Draguhn et al., 2014) , although the precise role of the different types of interneurons remains to be established. We found 5-HT 6 receptor mRNA to be expressed by a substantial portion of hippocampal 5-HT 3a receptor-and CB positive and, to a lesser degree, CR positive interneurons (Helboe et al., 2015) . It will be of great interest to study how these individual cell types that express the 5-HT 6 receptor contribute to the effects of idalopirdine on neuronal oscillations, neurotransmitter levels and ultimately cognition. In summary, we show that idalopirdine potentiates the effects of donepezil on elicited neuronal oscillations and extracellular levels of ACh in the hippocampus, two neurobiological mechanisms that are associated with cognitive function. This further supports the notion that the effects of an AChEI can be augmented by combined treatment with a 5-HT 6 receptor antagonist (Marcos et al., 2008; Bruin et al., 2011; Dawson, 2011) . The ability to increase the capacity for cholinergic transmission and evoked oscillations in the hippocampus, a brain region in which aberrant activity is observed early during the course of the disease, might provide an explanation for the cognitive improvements that are observed when idalopirdine is given as adjunct therapy to donepezil in patients with AD (Wilkinson et al., 2014) .
